SCHEMBL4121890

SCHEMBL4121890

NOCCCOc1ccc(C(F)(F)F)cn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
KMT2A Q03164 2/20 0.44
MAPK1 P28482 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
THRB P10828 1/20 0.41
IDO1 P14902 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GABRA5 P31644 1/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.40
RXRA P19793 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
RAB9A P51151 1/20 0.37
LIPE Q05469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6270313 0.97 MRGPRX4 (0.46) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL6267415 0.95 MRGPRX4 (0.45) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL3159889 0.86 HPGD (0.48) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL4699112 0.85 HPGD (0.47) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL16592115 0.83 MRGPRX4 (0.46) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL5079495 0.83 HPGD (0.48) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL2001524 0.83 HPGD (0.48) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL5076062 0.81 MRGPRX4 (0.47) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL10274190 0.81 HPGD (0.54) HPGDKMT2AMAPK1TSHRSMN1; SMN2
SCHEMBL2127040 0.81 HPGD (0.47) HPGDKMT2AMAPK1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
EP-1883622-A1 SUBSTITUTED ARYL OXIMES Bayer CropScience Aktiengesellschaft (DE) 2008-02-06 EP disclosed
WO-2007090434-A1 SUBSTITUTED ARYL OXIMES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2007-08-16 WO disclosed
WO-2005095330-A1 NOVEL DICHLOROPROPENE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2005-10-13 WO disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP disclosed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 HPGD 881/4885KMT2A 2985/4885MAPK1 1228/4885
US-20090221596-A1 Substtituted aryl oximes CYP1A1, PRDX1, CYP1A2 HPGD 2666/4885KMT2A 796/4885MAPK1 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.